Related Experiment Video

Updated: May 6, 2026

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

17.7K

[Intracellular targets : current data on effectiveness and safety profile]

R Alten1

  • 1Schlosspark-Klinik, Heubnerweg 2, 14059, Berlin, Deutschland, rieke.alten@schlosspark-klinik.de.

Zeitschrift Fur Rheumatologie
|November 7, 2013
PubMed

Insights

Protein kinase inhibitors offer a new way to treat rheumatoid arthritis (RA) by targeting immune pathways. Tofacitinib, a Janus kinase (JAK) inhibitor, is approved, with others in trials, raising safety and efficacy questions.

Area of Science:

  • Immunology
  • Pharmacology
  • Rheumatology

Context:

  • Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation.
  • Current RA treatments include conventional synthetic DMARDs, biological DMARDs, and targeted synthetic DMARDs.
  • Protein kinase inhibitors represent a novel class of targeted therapies for RA.

Purpose:

  • To review the efficacy and safety of protein kinase inhibitors for rheumatoid arthritis.
  • To compare the safety profile of kinase inhibitors with existing biological therapies.
  • To discuss the future role of intracellular kinase inhibitors in RA management.

Summary:

  • Protein kinase inhibitors target intracellular signaling pathways involved in cytokine-mediated inflammation in RA.
  • Tofacitinib, a Janus kinase (JAK) inhibitor, is the first approved drug in this class, with several others in clinical trials.
  • Key considerations for these novel therapies include their efficacy and safety compared to established biological treatments.

Impact:

  • Protein kinase inhibitors offer a promising new therapeutic avenue for RA patients.
  • Further research and clinical trials are needed to fully establish the long-term safety and efficacy of these agents.
  • These targeted therapies may shift the treatment paradigm for RA, potentially offering improved outcomes and safety profiles.

More Related Videos

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.2K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

11.6K

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
438
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
648
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129